March 2017 Issue of MMM

March 2017 Issue of MMM

Go Figure

Infographic: How Trump will affect healthcare marketing budgets

A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.

Editor's Desk

Another Pharmageddon? The Looming Threat to 2017 Ad Budgets

Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.

Digital Edition

Read the complete March 2017 digital edition

Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, ...


What uncertainty? 72% of health marketers say 2017 budgets are up

This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Guidemark Health's Sophy Regelous on why small budgets are increasing

Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.

Some CME experts remain skeptical when it comes to social media

There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.

Infographic: What's next for the point of care market

About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar ...


Why Philips' Erik Hollander turned to reinvention

He describes his current charge as "transforming a more creative occupation into a science."

Upward Move

QuintilesIMS taps Staub as head of R&D solutions

The merger of Quintiles and IMS Health closed in October.

Therapeutic Focus

Orphan drugs face criticism on prices — and from patients

When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

Roche gears up to enter loaded hemophilia A drug market

A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.

In Focus

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.

Partner Forum

4 Ways to Create a Dialogue With Patients Without Costly Studies

How can marketers incorporate patient feedback into their marketing strategies without expensive and time-consuming studies?

Beltway Insider

It's Time for Trump to Make Good on his Drug Pricing Promises

Last week President Trump told drugmakers that 'the pricing has been astronomical.'


Predicting Patient Behavior Improves the Brand Message

Few questions give healthcare marketers more heart palpitations than this one: "How do you know it will work?"

Why Pharma Refuses to See Value in 'Influence'

At the very least, pharma marketers need to make sure they know the difference between search engine marketing and search engine optimization.

Private View

Klick Health's Elliot Langerman on the Power of Persuasion

Here are six global campaigns that make the case for persuasion.

At Work With

MMC's Diana Littman on waiting for a decision after a pitch

She says her experience in consumer brands helps her push healthcare clients to be more creative.

Back Talk

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?